Alector Stock Price, News & Analysis

Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced presentations at two upcoming investor conferences. The first is at the Barclays Global Healthcare Conference in Miami, scheduled for March 16, 2022, at 3:20 p.m. ET. The second is the Stifel CNS Days Virtual event on March 28, 2022, at 11:30 a.m. ET. Both presentations will be available via live webcasts, with replays accessible for 90 days on Alector's website. Alector aims to treat neurodegenerative diseases by addressing immune dysfunction.

Alector (Nasdaq: ALEC) announced an oral presentation at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases, scheduled for March 15-20, 2022, in Barcelona, Spain. The presentation will showcase the 12-month results from the INFRONT-2 Phase 2 study of AL001 in Frontotemporal Dementia patients with a C9orf72 mutation. Alector will also host a conference call on March 15, 2022, at 8:30 a.m. ET to discuss these findings.

For more details, visit www.alector.com.

Alector, Inc. (Nasdaq: ALEC) announced on March 1, 2022, that its board's compensation committee granted newly appointed CFO, Marc Grasso, M.D., an inducement equity grant consisting of stock options for 450,000 shares. The options' exercise price is set at $15.49, matching the stock's closing price on the grant date. These options vest monthly over four years, contingent on Dr. Grasso's continued employment. Alector focuses on immuno-neurology, targeting immune dysfunction to develop therapies for neurodegenerative diseases.

Alector, a clinical-stage biotechnology company, will participate in a panel discussion at the Cowen Annual Health Care Conference on March 8, 2022, at 2:10 p.m. ET. The event will be available via a live webcast on Alector's 'Events & Presentations' page in the Investors section of their website. After the event, a replay will be accessible for 30 days. Alector focuses on immuno-neurology therapies targeting neurodegenerative diseases by repairing immune dysfunction and aims to develop treatments for conditions like frontotemporal dementia and Alzheimer’s disease.

Alector, Inc. (Nasdaq: ALEC) reported its fourth quarter and full year 2021 financial results. As of December 31, 2021, the company had cash reserves totaling $735.3 million, which increased to over $900 million after receiving a $200 million payment from GlaxoSmithKline (GSK) in January 2022. Collaboration revenue surged to $14 million for the quarter and $207 million for the year, significantly up from previous periods. However, Alector reported a net loss of $55.6 million in Q4 2021, slightly higher than the previous year's loss. The company anticipates sufficient funds to support operations through mid-2024.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, has appointed Dr. Marc Grasso as its new Chief Financial Officer. Dr. Grasso brings significant experience from Kura Oncology and leading investment banking roles. He will oversee financial operations and support corporate strategy, succeeding Linda Rubinstein, who served as interim CFO. Alector emphasizes its robust capital position and advanced clinical pipeline as it continues to develop therapies targeting neurodegenerative diseases.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced an inducement equity grant for its new President and Head of Research and Development, Dr. Sara Kenkare-Mitra, on January 3, 2022. The package includes stock options for 300,000 shares, 59,000 restricted stock units, and 59,000 performance stock units. The stock options have an exercise price of $20.78, and vesting schedules range from three to four years. The performance stock units are contingent on achieving stock price thresholds of $30 and $40 per share.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, has appointed Sara Kenkare-Mitra, Ph.D., as the new President and Head of Research and Development. This position aims to oversee the company’s R&D efforts in immuno-neurology and oncology. Dr. Kenkare-Mitra, formerly of Genentech, has over 23 years of experience, including significant contributions to drug approvals and clinical trials. Her expertise is expected to advance Alector's mission to develop innovative treatments for neurological diseases and cancers, enhancing both operational leadership and scientific goals.

Alector (NASDAQ: ALEC) announced positive results from its Phase 2 INFRONT-2 clinical trial of AL001 for frontotemporal dementia (FTD) patients with progranulin gene mutations. The treatment successfully restored progranulin levels to normal and showed a 48% reduction in clinical progression compared to a matched control cohort over 12 months. Biomarkers for disease severity, including GFAP, also improved. The company aims to advance to the Phase 3 INFRONT-3 study, seeking to further evaluate AL001’s efficacy and safety.